Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study.
Jiandong ZhouGuoming ZhangCarlin ChangOscar Hou-In ChouSharen LeeKeith Sai Kit LeungWing Tak WongTong LiuAbraham Ka Chung WaiShuk Han ChengQingpeng ZhangGary TsePublished in: Acta diabetologica (2022)
Sulphonylurea use was associated with higher risks of incident AF, stroke, cardiovascular mortality and all-cause mortality compared to metformin. Males and patients older than 65 years with sulphonylurea use were exposed to the highest risks.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- end stage renal disease
- catheter ablation
- left atrial appendage
- ejection fraction
- newly diagnosed
- direct oral anticoagulants
- heart failure
- human health
- cardiovascular disease
- prognostic factors
- percutaneous coronary intervention
- peritoneal dialysis
- physical activity
- type diabetes
- risk assessment
- venous thromboembolism
- patient reported